Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

British Journal of Cancer

Volumn 113, Issue 12, 2015, Pages 1687-1693

  Colmegna, B ^a   Uboldi, S ^a   Frapolli, R ^a   Licandro, S A ^a   Panini, N ^a   Galmarini, C M ^b   Badri, Nadia ^b   Spanswick, V J ^c   Bingham, J P ^c   Kiakos, Konstantinos ^c   Erba, E ^a   Hartley, J A ^c   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PHARMAMAR S A   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cis DDP; collateral sensitivity; DNA repair; ovarian cancer; resistance; Trabectedin

Indexed keywords

BETA ACTIN; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE H2AX; MESSENGER RNA; TRABECTEDIN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; H2AFX PROTEIN, HUMAN; HISTONE; PLATINUM COMPLEX; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; EXCISION REPAIR; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; MYXOSARCOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DIOXOLES; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONES; HUMANS; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952639721     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.407     Document Type: Article

References (36)

1. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 76: 19-27.
2. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9: 2157-2163.
3. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92: 583-588.
4. de Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13: 768-785.
5. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM (2009) H2AX: functional roles and potential applications. Chromosoma 118: 683-692.
6. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ (2009) ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS One 4: e6967.
7. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97-105.
8. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M (2000) Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 82: 1732-1739.
9. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8: 449-457.
10. Guirouilh-Barbat J, Redon C, Pommier Y (2008) Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 19: 3969-3981.
11. Hartley JM, Spanswick VJ, Hartley JA (2011) Measurement of DNA damage in individual cells using the single cell gel electrophoresis (Comet) assay. Methods Mol Biol 731: 309-320.
12. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006) Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66: 8155-8162.
13. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97: 6775-6779.
14. Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1: 1327-1334.
15. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
16. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K (2005) The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27: 1605-1616.
17. Marchini S, Marrazzo E, Bonomi R, Chiorino G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggini M, Faircloth GT, D'Incalci M (2005) Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 41: 323-333.
18. Minuzzo M, Ceribelli M, Pitarque-Marti M, Borrelli S, Erba E, DiSilvio A, D'Incalci M, Mantovani R (2005) Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 68: 1496-1503.
19. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97: 6780-6784.
20. Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A (2015) Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol 26: 914-920.
21. Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 122: 86-94.
22. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35: 13303-13309.
23. Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N (2014) Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat Rev 40: 366-375.
24. Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R (2014) Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res 74: 6980-6990.
25. Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, Garcia-Fernandez LF, Cuevas C, Allavena P, Erba E, D'Incalci M (2013) Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104). Int J Cancer 133: 2024-2033.
26. Shao L, Kasanov J, Hornicek FJ, Morii T, Fondren G, Weissbach L (2003) Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 66: 2381-2395.
27. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA (2005) Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 70: 59-69.
28. Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser D, Hartley JA (2012) Evidence for different mechanisms of 'unhooking' for melphalan and cisplatininduced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer 12: 436.
29. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC, Pommier Y (2008) Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 7: 10-18.
30. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7: 961-966.
31. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M (2007) Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif 40: 885-904.
32. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G (2008) Role of homologous recombination in trabectedininduced DNA damage. Eur J Cancer 44: 609-618.
33. Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M (2012) Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer 131: 59-69.
34. Wood RD (2010) Mammalian nucleotide excision repair proteins and interstrand crosslink repair. Environ Mol Mutagen 51: 520-526.
35. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
36. Zewail-Foote M, Hurley LH (2001) Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J Am Chem Soc 123: 6485-6495.